Trial Profile
A Randomized, Multi-Center, Parallel-Group, Safety and Efficacy Study of Lotemax Gel 0.5% and Restasis 0.05% for 12 Weeks in Subjects With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease; DED)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Loteprednol etabonate (Primary) ; Allantoin; Ciclosporin
- Indications Keratoconjunctivitis sicca
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bausch & Lomb
- 20 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 03 Dec 2013 New trial record